MPR News Chief Meteorologist Paul Huttner signs off

MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all. 

Turn Up Your Support

The Food and Drug Administration has approved the first in a class of generic drugs that are made from living cells instead of chemical compounds.

 "are complex medications made or extracted from living cells, blood components and tissue," 

The newspaper adds: "Biosimilars, unlike traditional generics, aren't precisely identical to the brand drug.

The FDA says biosimiliars must have no "clinically meaningful differences" in safety or effectiveness and must work in the same way as the drugs they are meant to substitute.


The FDA said Friday it has approved the first biosimilar, a drug called Zarxio that is made by 

 and meant to boost white blood cells in chemotherapy patients.


As NPR's Rob Stein reports, the decision is expected to open the door to getting many more, less costly versions of expensive drugs on the market.

Zarxio is a generic version of a drug that costs more than $3,000 for a one-month regimen. The biosimilar version costs about $1,000.


Rob notes: "That may not sound like a lot. But the drug's used a lot. So, according to one estimate, the cheaper, generic version could save the U.S. health care system nearly $6 billion over the next decade."  Copyright 2019 NPR. To see more, visit https://www.npr.org.

Science

Health

These "biosimilar" drugs closely mimic existing drugs but are made from living cells, blood components and tissue. In some cases, they could cut drugs costs.

FDA approves first of new type of generic drugs

Go Deeper.

Like this?

News you can use in your inbox